<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(4)</volume><submitter>Su SS</submitter><pubmed_abstract>&lt;h4>Background &amp; aims&lt;/h4>The cellular immunity has a profound impact on the status of hepatitis C virus (HCV) infection. However, the response of cellular immunity on the virological response in patients with antiviral treatment remains largely unclear. We aimed to clarify the response of peripheral T cells and monocytes in chronic hepatitis C patients with antiviral treatment.&lt;h4>Methods&lt;/h4>Patients with chronic hepatitis C were treated either with interferon alpha-2b plus ribavirin (n = 37) or with pegylated interferon alpha-2a plus ribavirin (n = 33) for up to 24 weeks. Frequencies of peripheral regulatory T-cells (Tregs), programmed death-1 (PD-1) expressing CD4+ T-cells or CD8+ T-cells and toll-like receptor (TLR) 3 expressing CD14+ monocytes were evaluated by flow cytometry in pati</pubmed_abstract><journal>PloS one</journal><pagination>e93620</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3977904</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trial.</pubmed_title><pmcid>PMC3977904</pmcid><pubmed_authors>Kong LB</pubmed_authors><pubmed_authors>He H</pubmed_authors><pubmed_authors>Zhang YG</pubmed_authors><pubmed_authors>Zheng HW</pubmed_authors><pubmed_authors>Su SS</pubmed_authors><pubmed_authors>Nan YM</pubmed_authors><pubmed_authors>Zhao SX</pubmed_authors><pubmed_authors>Yu J</pubmed_authors><pubmed_authors>Wang RQ</pubmed_authors><pubmed_authors>Sun DX</pubmed_authors></additional><is_claimable>false</is_claimable><name>Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trial.</name><description>&lt;h4>Background &amp; aims&lt;/h4>The cellular immunity has a profound impact on the status of hepatitis C virus (HCV) infection. However, the response of cellular immunity on the virological response in patients with antiviral treatment remains largely unclear. We aimed to clarify the response of peripheral T cells and monocytes in chronic hepatitis C patients with antiviral treatment.&lt;h4>Methods&lt;/h4>Patients with chronic hepatitis C were treated either with interferon alpha-2b plus ribavirin (n = 37) or with pegylated interferon alpha-2a plus ribavirin (n = 33) for up to 24 weeks. Frequencies of peripheral regulatory T-cells (Tregs), programmed death-1 (PD-1) expressing CD4+ T-cells or CD8+ T-cells and toll-like receptor (TLR) 3 expressing CD14+ monocytes were evaluated by flow cytometry in pati</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014</publication><modification>2026-05-07T00:51:07.993Z</modification><creation>2019-03-26T23:25:34Z</creation></dates><accession>S-EPMC3977904</accession><cross_references><pubmed>24709775</pubmed><doi>10.1371/journal.pone.0093620</doi></cross_references></HashMap>